All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
The vector of anti-GD2 chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human GD2. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-GD2 antibody linked to 4-1BB and CD3ζ signaling domains. And the vector product was designed for the treatment of Neuroblastoma; melanoma.
|
CAR Construction : 3F8 scfv-CD28-41BB-CD3ζ-icasp9
Fig.5 Anti-GD2 CART cells are depleted upon stimulation with GD2(C) target cells in vitro. T cells that were transduced with the hu3F8CAR (anti-GD2) and expanded for 8 d thereafter were stimulated with irradiated IMR32luc (GD2+) or THP1 (GD2-) cells. After 1, 2, and 4 d, cells were counted and CAR expression was assessed by anti-idiotype antibody (A1G4). Dead cells were excluded by Annexin-V staining. Absolute cell number was calculated based on flow cytometry. Hoseini, Sayed Shahabuddin, et al. "Bispecific antibody does not induce T-cell death mediated by chimeric antigen receptor against disialoganglioside GD2." Oncoimmunology 6.6 (2017): e1320625. Distributed under Open Access license CC BY 4.0, without modification. |
|
CAR Construction : 3F8 scfv-CD28-41BB-CD3ζ-icasp9
Fig.6 Anti-GD2 CART cells are depleted upon stimulation with GD2(C) target cells in vitro. T cells that were transduced with the hu3F8CAR (anti-GD2) and expanded for 8 d thereafter were stimulated with irradiated IMR32luc (GD2+) or THP1 (GD2-) cells. After 1, 2, and 4 d, cells were counted and CAR expression was assessed by anti-idiotype antibody (A1G4). Dead cells were excluded by Annexin-V staining. Absolute cell number was calculated based on cell count. Hoseini, Sayed Shahabuddin, et al. "Bispecific antibody does not induce T-cell death mediated by chimeric antigen receptor against disialoganglioside GD2." Oncoimmunology 6.6 (2017): e1320625. Distributed under Open Access license CC BY 4.0, without modification. |
|
CAR Construction : 3F8 scfv-CD28-41BB-CD3ζ-icasp9
Fig.7 Lowering CAR affinity cannot prevent CART cell depletion upon antigen exposure. T cells that were transduced with the 2nd-generation hu3F8 (loweraffinity) or hu3F8(D32H-E1K) (higher-affinity) CARs, and expanded thereafter for 8 d were stimulated with irradiated IMR32luc (GD2+) or THP1 (GD2-) cells. One day later, cells were assessed by flow cytometry for CAR expression. Hoseini, Sayed Shahabuddin, et al. "Bispecific antibody does not induce T-cell death mediated by chimeric antigen receptor against disialoganglioside GD2." Oncoimmunology 6.6 (2017): e1320625. Distributed under Open Access license CC BY 4.0, without modification. |
|
CAR Construction : 3F8 scfv-CD28-41BB-CD3ζ-icasp9
Fig.8 Lowering CAR affinity cannot prevent CART cell depletion upon antigen exposure. T cells that were transduced with the 1st-generation or 2nd-generation hu3F8 CARs, and expanded thereafter for 8 d were stimulated with irradiated IMR32luc (GD2+) or THP1 (GD2-) cells. One day later, cells were assessed by flow cytometry for CAR expression. Hoseini, Sayed Shahabuddin, et al. "Bispecific antibody does not induce T-cell death mediated by chimeric antigen receptor against disialoganglioside GD2." Oncoimmunology 6.6 (2017): e1320625. Distributed under Open Access license CC BY 4.0, without modification. |
|
CAR Construction : 3F8 scfv-CD28-41BB-CD3ζ-icasp9
Fig.9 GD2-specific CART cell depletion severely compromises their function in short-term killing assays. T cells that were transduced with the hu3F8CAR and expanded thereafter for 8 d were stimulated with irradiated IMR32luc (GD2+) or THP1 (GD2-) cells. Four days later, hu3F8CART cells were tested against IMR32luc targets in a 4-h 51Cr-release assay. Hoseini, Sayed Shahabuddin, et al. "Bispecific antibody does not induce T-cell death mediated by chimeric antigen receptor against disialoganglioside GD2." Oncoimmunology 6.6 (2017): e1320625. Distributed under Open Access license CC BY 4.0, without modification. |
|
CAR Construction : 3F8 scfv-CD28-41BB-CD3ζ-icasp9
Fig.10 Surviving CART cells retain a significant antitumor cytotoxicity in long-term killing assays. Hu3F8CART cells were exposed to GD2(+) IMR32luc cells in triplicates for 3 d at an E:T=1. On day 3, cells were harvested, counted, and mixed with fresh IMR32luc targets (E:T=1). After 4 more days, cells were counted and assessed by flow cytometry. Number of live target cells was calculated based on cell count. Hoseini, Sayed Shahabuddin, et al. "Bispecific antibody does not induce T-cell death mediated by chimeric antigen receptor against disialoganglioside GD2." Oncoimmunology 6.6 (2017): e1320625. Distributed under Open Access license CC BY 4.0, without modification. |
|
CAR Construction : 3F8 scfv-CD28-41BB-CD3ζ-icasp9
Fig.11 Surviving CART cells retain a significant antitumor cytotoxicity in long-term killing assays. Hu3F8CART cells were exposed to GD2(+) IMR32luc cells in triplicates for 3 d at an E:T=1. On day 3, cells were harvested, counted, and mixed with fresh IMR32luc targets (E:T=1). After 4 more days, cells were counted and assessed by flow cytometry. Number of live target cells was calculated based on flow cytometry. Hoseini, Sayed Shahabuddin, et al. "Bispecific antibody does not induce T-cell death mediated by chimeric antigen receptor against disialoganglioside GD2." Oncoimmunology 6.6 (2017): e1320625. Distributed under Open Access license CC BY 4.0, without modification. |
|
CAR Construction : 3F8 scfv-CD28-41BB-CD3ζ-icasp9
Fig.12 Anti-GD2 CAR-T cells cure melanoma tumors in vivo. Immunodeficient DKO mice were subcutaneously inoculated with GD2(+) M14luc human melanoma xenografts (4E6 cells). CART Therapy was started after 7 d. Tumor volume was measured weekly. Hoseini, Sayed Shahabuddin, et al. "Bispecific antibody does not induce T-cell death mediated by chimeric antigen receptor against disialoganglioside GD2." Oncoimmunology 6.6 (2017): e1320625. Distributed under Open Access license CC BY 4.0, without modification. |
More Published Data More Published Data
There are currently no customer reviews or questions for Anti-GD2 (3F8) h(4-1BB-CD3ζ) CAR, pCDCAR1 (CAR-YF203). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION